Lenascience Inc. has initiated Phase I clinical trials in collaboration with KAIMRC in Saudi Arabia, scheduled to be completed by the end of December 2026. The clinical trial evaluates the safety and tolerability of RS5614, with plans to proceed to Phase II trials thereafter.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4889","jir_company_name":"Lenascience Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-07-21","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4889-20260721-01.pdf","jir_short_summary":"Lenascience Inc. has initiated Phase I clinical trials in collaboration with KAIMRC in Saudi Arabia, scheduled to be completed by the end of December 2026. The clinical trial evaluates the safety and tolerability of RS5614, with plans to proceed to Phase II trials thereafter.","jir_summary":"### Overview of the Clinical Trial\nLenascience Inc., in collaboration with KAIMRC in Saudi Arabia, has commenced Phase I clinical trials of RS5614. The trial evaluates safety and tolerability and is scheduled to be completed by the end of December 2026. The trial is conducted in Saudi Arabia and represents an important step toward future Phase II trials.\n\n### Future Outlook and Impact on Performance\nDepending on the results of this clinical trial, development of anti-aging and longevity therapeutics is expected to progress, with potential future commercialization and revenue generation. However, at this stage, the direct impact on performance is expected to be minimal, and additional information will be disclosed as developments occur.","jir_financial_highlights":"Start Date of Clinical Trial: 2026-07-21 (Unknown)\nScheduled Completion Date: 2026-12-31 (Unknown)\nClinical Trial Costs: Unknown (Unknown)","jir_category":"","jir_hashtags":"#Lenascience, #IRTypeRelated, #JapaneseStocks","jir_key_figures":"Start Date of Clinical Trial: 2026-07-21\nScheduled Completion Date: 2026-12-31\nClinical Trial Costs: Unknown","jir_meta_title":"\u3010Lenascience\u3011Start of Clinical Trial in Saudi Arabia | July 2026","jir_meta_description":"Lenascience Inc. has initiated Phase I clinical trials in Saudi Arabia with KAIMRC, evaluating safety. Overview of future prospects and impact on performance.","jir_og_title":"\u3010Lenascience\u3011Start of Clinical Trial in Saudi Arabia | July 2026","jir_og_description":"Lenascience has begun clinical trials in Saudi Arabia with KAIMRC. Detailed information on safety evaluation and future outlook.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57877,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-85998","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n